Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria
Clinical Pharmacology and Therapeutics, Volume 91, No. 3, Year 2012
Notification
URL copied to clipboard!
Description
Dihydroartemisinin-piperaquine is being increasingly used as a first-line artemisinin combination treatment for malaria. The aim of this study was to describe the pharmacokinetic and pharmacodynamic properties of piperaquine in 236 children with uncomplicated falciparum malaria in Burkina Faso. They received a standard body weight-based oral 3-day fixed-dose dihydroartemisinin- piperaquine regimen. Capillary plasma concentration-time profiles were characterized using nonlinear mixed-effects modeling. The population pharmacokinetics of piperaquine were described accurately by a two-transit-compartment absorption model and a three-compartment distribution model. Body weight was a significant covariate affecting clearance and volume parameters. The individually predicted day 7 capillary plasma concentration of piperaquine was an important predictor (P<0.0001) of recurrent malaria infection after treatment. Young children (2-5 years of age) received a significantly higher body weight-normalized dose than older children (P = 0.025) but had significantly lower day 7 piperaquine concentrations (P = 0.024) and total piperaquine exposures (P = 0.021), suggesting that an increased dose regimen for young children should be evaluated. © 2012 american Society for clinical Pharmacology and Therapeutics.
Authors & Co-Authors
Tarning, Joel
Thailand, Nakhon Pathom
Mahidol University
United Kingdom, Oxford
Nuffield Department of Medicine
Zongo, Issaka D.
Burkina Faso, Ouagadougou
Institut de Recherche en Sciences de la Santé
Somé, Fabrice Anyirékun
Burkina Faso, Ouagadougou
Institut de Recherche en Sciences de la Santé
Rouamba, Noël
Burkina Faso, Ouagadougou
Institut de Recherche en Sciences de la Santé
Parikh, Sunil
United States, San Francisco
Ucsf School of Medicine
Rosenthal, Philip Jon
United States, San Francisco
Ucsf School of Medicine
Hanpithakpong, Warunee
Thailand, Nakhon Pathom
Mahidol University
Jongrak, N.
Thailand, Nakhon Pathom
Mahidol University
Day, Nichloas P.J.
Thailand, Nakhon Pathom
Mahidol University
United Kingdom, Oxford
Nuffield Department of Medicine
White, Nicholas J.
Thailand, Nakhon Pathom
Mahidol University
United Kingdom, Oxford
Nuffield Department of Medicine
Nosten, François Henry
Thailand, Nakhon Pathom
Mahidol University
United Kingdom, Oxford
Nuffield Department of Medicine
Thailand, Mae Sod
Shoklo Malaria Research Unit
Ouedraogo, Jean Bosco
Burkina Faso, Ouagadougou
Institut de Recherche en Sciences de la Santé
Lindegårdh, Niklas
Thailand, Nakhon Pathom
Mahidol University
United Kingdom, Oxford
Nuffield Department of Medicine
Statistics
Citations: 101
Authors: 13
Affiliations: 5
Identifiers
Doi:
10.1038/clpt.2011.254
ISSN:
00099236
e-ISSN:
15326535
Research Areas
Health System And Policy
Infectious Diseases
Maternal And Child Health
Study Design
Cross Sectional Study
Study Locations
Burkina Faso